A Brain-Targeting Curcumin Analog Inhibits Glioblastoma Progression Through THBS1/TGF-β1/PI3K-AKT Axis Modulation:...

Area of Science:

• Neuro-oncology
• Molecular Biology
• Drug Discovery

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor outcomes.
• Novel therapeutic strategies are urgently needed.
• The direct mechanisms of action for brain-targeted curcumin analogs like DMC-GF on GBM cells are not fully understood.

Purpose of the Study:

• To systematically investigate the molecular mechanisms by which DMC-GF exerts anti-GBM effects.
• To identify key molecular targets and pathways modulated by DMC-GF.
• To evaluate DMC-GF as a potential therapeutic candidate for GBM.

Main Methods:

• Phenotypic assays to assess cell proliferation, migration, invasion, and apoptosis.
• Transcriptome sequencing and bioinformatics analysis to identify molecular targets.
• Functional experiments including gene knockdown and overexpression.
• Mechanistic studies to elucidate signaling pathway modulation.

Main Results:

• DMC-GF demonstrated dose-dependent inhibition of GBM cell proliferation, migration, and invasion, while promoting apoptosis.
• Transcriptomic analysis identified THBS1 as a key downstream target suppressed by DMC-GF.
• DMC-GF was found to suppress the non-canonical TGF-β1 pathway by downregulating THBS1, subsequently inhibiting PI3K/AKT signaling.
• THBS1 knockdown mimicked DMC-GF's anti-tumor effects, while THBS1 overexpression partially reversed them.

Conclusions:

• DMC-GF exerts anti-GBM effects by modulating the THBS1/TGF-β1/PI3K-AKT signaling axis.
• DMC-GF shows promise as a brain-targeted therapeutic agent for GBM.
• This study provides crucial mechanistic insights for overcoming therapeutic resistance in GBM.